Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-05
2006-09-05
Bugaisky, Gabriele (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S325000, C530S300000, C435S007200
Reexamination Certificate
active
07101849
ABSTRACT:
An isolated, synthetic, or recombinant ω-conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises SEQ ID NO: 1 or such a sequence which has undergone one or more amino acid substitutions or side chain modifications, and uses therefor. SEQ ID NO: 1 comprises the amino acid sequence SGTVGR.
REFERENCES:
patent: 5364842 (1994-11-01), Justice et al.
patent: 5424218 (1995-06-01), Miljanich et al.
K.J. Nielsen et al., (1996) “A Consensus Structure for ω-Conotoxins with Different Selectivities for Voltage-sensitive Calcium Channel Subtypes: Comparison of MVIIA, SVIB and SNX-202”, (Journal of Molecular Biology, vol. 263, pp. 297-310.
K. Sato et al. (1997), “Binding of Chimeric Analogs of ω-Conotoxin MVIIA and MVIIC to the N-and P70-type Calcium Channels”, (FEBS Letters, vol. 414, pp., 480-484.
Alewood Paul Francis
Drinkwater Roger Desmond
Lewis Richard James
Nielsen Katherine Justine
Bugaisky Gabriele
Scully Scott Murphy & Presser
The University of Queensland
LandOfFree
ωconotoxin peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ωconotoxin peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ωconotoxin peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559761